LDK378

Showing 1 posts of 1 posts found.

Promising signs for Novartis’ lung cancer drug

June 4, 2013
Sales and Marketing ALK+, ASCO, LDK378, NSCLC, Novartis

Targeted lung cancer treatment LDK378 has been shown to help patients with the ALK+ gene mutation in a phase I trial.Novartis’ drug …

The Gateway to Local Adoption Series

Latest content